# US 2026/0060944 A1 · Pharmaceutical composition and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060944 A1
- Document ID: US20260060944A1
- Status: Published application
- Kind: A1
- Application number: 19/107,043
- Filed: 2023-08-29
- Published: 2026-03-05
- Earliest claimed: 2022-08-29
- Inventors: Kuei-Chung Shih
- Web page: https://patentgrep.com/patent/US20260060944A1

## CPC

- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 31/145: having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2) (isothiourea A61K31/155)
- A61K 31/64: Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
- A61K 33/00: Medicinal preparations containing inorganic active ingredients
- A61K 33/06: Aluminium, calcium or magnesium; Compounds thereof {, e.g. clay}
- A61K 33/26: Iron; Compounds thereof
- A61K 33/30: Zinc; Compounds thereof
- A61K 33/32: Manganese; Compounds thereof
- A61K 33/34: Copper; Compounds thereof
- A61P 35/00: Antineoplastic agents
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A pharmaceutical composition includes: (a) a targeting agent for cancer cell mitochondria, (b) an ion chelating agent, and (c) pharmacologically active multivalent ions. The weight ratio of (a) is 64.5%˜43.7% based on the total weight of the pharmaceutical composition, the weight ratio of (b) is 56.2%˜16.1% based on the total weight of the pharmaceutical composition; the weight ratio of (c) is 19.4%˜0.000116% based on the total weight of the pharmaceutical composition.

## Claims

### Claim 1

A pharmaceutical composition, comprising:
(a) a targeting agent for a mitochondrion of a cancer cell;
(b) an ion chelating agent; and
(c) a pharmacologically active multivalent ion, wherein the targeting agent for the mitochondrion of the cancer cell is Niclosamide, the ion chelating agent is Disulfiram, and the pharmacologically active multivalent ion is selected from a group consisting of a magnesium ion, a calcium ion, a manganese ion, a ferrous ion, a copper ion, and a zinc ion, and a weight ratio of (a) is 64.5%˜43.7% based on a total weight of the pharmaceutical composition, a weight ratio of (b) is 56.2%˜16.1% based on the total weight of the pharmaceutical composition, and a weight ratio of (c) is 19.4%˜0.000116% based on the total weight of the pharmaceutical composition.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein 0.091≤(a)/((b)+(c))≤15.548.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein 0.214≤(b)/(c)≤1.8867×104.

### Claim 4 (depends on 1, 2, 3)

Use of the pharmaceutical composition as claimed in claim 1 or claim 2 or claim 3 in preparing a medicament for treating a malignant tumor in an individual in need.

### Claim 5 (depends on 4)

The use of claim 4, wherein the malignant tumor is selected from a group consisting of a solid tumor and a hematological malignant disease.

### Claim 6 (depends on 5)

The use of claim 5, wherein the malignant tumor is selected from a group consisting of lung cancer and brain cancer.

### Claim 7 (depends on 4)

The use of claim 4, wherein (a) a dose per administration ranges from 2000 mg to 100 mg, (b) a dose per administration ranges from 500 mg to 128.6 mg, and (c) a dose per administration ranges from 600 mg to 2.65×10−4 mg.

### Claim 8 (depends on 4)

The use of claim 4, wherein administration of (c) is performed no later than administration of (b).

### Claim 9 (depends on 4)

The use of claim 4, wherein the medicament is administered no more than twice per day.

### Claim 10 (depends on 4)

The use of claim 4, wherein the medicament is administered via an oral route, an injected route, a transdermal route, or an inhaled route.
